Our Fight Against Cancer Kintara Therapeutics is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara Therapeutics has teamed up with outstanding academic and clinical research institutions from around the world to support the development of our novel cancer therapies. A Pipeline of Breakthrough Cancer Therapeutics VAL-083 is a first-in-class small molecule DNA-targeting agent that exhibits a novel mechanism of action that results in DNA double strand breaks and cancer cell death. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types. VAL-083's indications include: Glioblastoma Multiforme (GBM) Ovarian Cancer Pediatric CNS Tumors REM-001 is a second generation photosensitizer drug possessing multiple advantages over earlier generation PDT compounds. REM-001’s indications include: Cutaneous Metastatic Breast Cancer Recurrent Basal Cell Carcinoma Nevus Syndrome Hemodialysis Arteriovenous (AV) Access
View Top Employees from Kintara Therapeutics, Inc. NASDAQ: KTRAWebsite | https://www.kintara.com/ |
Employees | 7 (2 on RocketReach) |
Founded | 2010 |
Address | 12707 High Bluff Dr Suite 200, San Diego, California 92130, US |
Industry | Biotechnology Research, Drug Discovery |
Looking for a particular Kintara Therapeutics, Inc. NASDAQ: KTRA employee's phone or email?
Robert Hoffman is the President and Chief Executive Officer of Kintara Therapeutics, Inc. NASDAQ: KTRA.
2 people are employed at Kintara Therapeutics, Inc. NASDAQ: KTRA.
Kintara Therapeutics, Inc. NASDAQ: KTRA is based in San Diego, California.